Google Custom Search

Update on Tibotec's REACH Initiative for Resource-Poor Countries

Tibotec Therapeutics recently announced a 2008 Request for Proposals (RFP) for the "Research and Education in HIV/AIDS for Resource-Poor Countries" (REACH) initiative. Letters of intent for the second annual REACH initiative grants are now being accepted.

The goal of the REACH initiative is to foster the work of emerging biomedical and social researchers and educators working on HIV/AIDS treatment and prevention in resource-poor settings in Africa, Asia, Latin America, and Eastern Europe.

The initiative supports collaborative projects between organizations in the developed and developing world. We would also like to encourage grant requests addressing the needs of women and girls.

Requests to the REACH Initiative should focus on innovations in research and/or education for resource-poor countries that result in one or more of the following:

Optimizing treatment and care;

Development of new or more cost-effective diagnostic, treatment, or prevention technologies;

The integration of bio-medical and social research;

Development of new or improvements in existing approaches to healthcare worker training and education

The initiative is managed by a program committee led by Dr. Michael Saag, Professor of Medicine, University of Alabama Center for AIDS Research and Dr. Joep Lange, Professor of Medicine, Academic Medical Center, University of Amsterdam, in partnership with Tibotec.

Applicants should submit a summary of their organizations and a one-page letter of intent explaining their request and the intended impact/outcome. All requests should be emailed to REACH@tttus.jnj.com and must be received by March 13, 2008.

In the initiative's first year, 10 grants were provided to recipients in 15 countries. For a profile of last year's grantees and for more information on how to apply for grant funding from the REACH Initiative, including submission requirements, visit www.tibotec.com.

01/15/08

Source
Tibotec Therapeutics.

HIV and AIDS Main Section
FDA-approved Treatments for HIV and AIDS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Protease Inhibitors
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir hard gel)
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
ViraceptViracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
CombivirCombivir (zidovudine/lamivudine)
EpivirEpivir (lamivudine; 3TC)
EmtrivaEmtriva (emtricitabine; FTC)
EpzicomEpzicom (abacavir + lamivudine)
RetrovirRetrovir (zidovudine; AZT)
TrizivirTrizivir (abacavir + zidovudine +lamivudine)
TruvadaTruvada  (tenofovir / emtricitabine)
VidexVidex (didanosine; ddI)
VireadViread (tenofovir)
ZeritZerit (stavudine; d4T)
ZiagenZiagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
RescriptorRescriptor (delavirdine)
SustivaSustiva (efavirenz)
ViramuneViramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
AtriplaAtripla (efavirenz + emtricitabine + tenofovir)
CombivirCombivir (zidovudine + lamivudine)
TrizivirTrizivir (abacavir + zidovudine + lamivudine)
TruvadaTruvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)